MedTrace Logo

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

NCT01827592 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2015-10-20

Study results available
· View outcomes & findings →

Summary

Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.

Conditions

  • Chronic Idiopathic Constipation

Interventions

DRUG

Elobixibat 10 mg

Elobixibat 10 mg/day

DRUG

Elobixibat 5 mg

Elobixibat 5 mg/day

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-03-31
Completion
2014-05-31

Countries

  • United States
  • Belgium
  • Brazil
  • Canada
  • Czechia
  • Germany
  • Israel
  • Poland
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827592 on ClinicalTrials.gov